RE:RE:Safety is more important...Hmm. It's a theory based on facts that did occur in a sequential time-line that fits the delayed treatment of additional patients. It's well thought out, with plausable conclusions.
I also have a few comments regarding the "excessive" Administrative Expenses, moving to the NASDAQ." (A) Corporate leadership has to continue to buy shares to have any form of company control if there were to be a hostile takeover attempt. Where do you think R.D., C.H et.al are getting the funds to continue to buy during the PP's? The more they buy, the better I feel about management participation in the risk. Those who participate in the PP's are aware too.
(B) Roger and C.H. have too much invested to run the risk of a RS in an effort to gain access to the new marketplace. And a RS strategy is at the very high end of risk. Further, unless that move is supported by more than a few deep pocket friendly investment companies - Vultures will short it to pennies from where it's required (above $4.00/share) to qualify to uplist. It will take hundreds of millions to defend the stock if it moves too far ahead of the known success of any cancer treatments. IMO TLT will stay on a Canadian exchange until a merger with another corp. that's already on a US exchange. There's no risk staying in Canada until we merge. I am aware that treating and/or curing cancer is more than a hundred billion dollar market. Righ now I think TLT is on all companies radar that are currently treating cancer with chemo, or other potiential drugs. I'd say Ruvidar has the most potential to change the dynamics of treating cancer. That's a lot of risk to those corp's that are reaping billions as a treatment. IMO.
GLTA, BK